Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm so fixed from mainlining leronlimab I have to inject the shite between my toes
sloppy attempt ???--Sounds like the ramblings of a terrified and nervous bagholder.
Every word quoted is directly from the Wall Street Journal.
As the stock trends closer and closer to zero, new bagholder aliases are getting flushed out into the open left and right.
If "the big boys want it" they can wait until June 1, 2024 when it goes off patent and get it for free without the deadweight that is cydy.
Will the felon end up at Leavenworth or Attica? For those that dismiss his prior felonies, did his ex-wife have a restraining order against him? Did he used to beat her?
Absolutely. The last time I saw brucie I was so hyped on leronlimab I banged out a line of it and got high af
What is your point. Even after Bruce & Cyto parted ways, months later he still thought is was a drug worth attention from operation warp speed. The whole point of operation warp speed was to have less red tape for an effective drug to save human lives.
Slow down justafacts, i know it's almost quitting time, but at least come up with something that attempts at being a slam, . Your bosses are not going to be happy with your sloppy attempt.
What about Brucie pumping Operation Warp Speed?---
Small Biotech Stock CytoDyn Soars on ‘Warp Speed’ Comment
By Michael Wursthorn
Updated Aug. 26, 2020 9:18 pm ET
The market for small biotechs working on coronavirus treatments is so hot that sometimes all it takes is a whisper to send a stock soaring.
So it was with CytoDyn Inc. , which climbed more than 20% after a former adviser told television host Dr. Drew Pinksy on Thursday that he thought the company would move forward with a federal-government program aimed at fast- tracking virus treatments.
CytoDyn isn't being considered for the program, known as Operation Warp Speed, according to a senior administration official.
Yet in the quick-punch world of retail investing, the video clip of the former adviser, Bruce Patterson , has already gone viral. Investors who closely follow the company shared it on social media and message boards, including Investors Hub, a forum popular with penny-stock traders. Shares of CytoDyn rallied 13% to $3.43 a share on Friday, notching the company's biggest daily gain in about a month, before rising another 12% on Monday.
CytoDyn Shares have plateaued since then, declining a more than 2% over the last two trading sessions.
Operation Warp Speed is a federal initiative to accelerate the development and manufacturing of drugs and vaccines for Covid-19, which has claimed more than 175,000 lives in the U.S. Through the program, the government has given funding to companies such as Moderna Inc. , Novavax Inc. and Regeneron Pharmaceuticals Inc.
The senior administration official said CytoDyn had only completed a preliminary qualification for being included in the initiative. The Vancouver, Wash ., company had submitted information through a so-called CoronaWatch, a program run by the Biomedical Advanced Research and Development Authority , or Barda, to assess the viability of drugs and therapeutics that might be effective against Covid-19, the official said. Technical experts reviewed the submission and opted not to proceed further at this time, the official added.
The team responsible for reviewing the materials makes clear to companies that submissions are for informational purposes only and don't lead to funding on their own, the official added. Companies must apply to specific grant programs to receive funding, the official said, which CytoDyn hasn't done at this time.
Dr. Patterson told The Wall Street Journal that he helped arrange an initial exchange of information between CytoDyn and Barda. He hadn't been involved in further discussions, he said.
CytoDyn declined to comment on the exchange or on any communication with Operation Warp Speed.
" CytoDyn received an email. I received an email from Operation Warp Speed. So yes they are aware of it," Dr. Patterson said in the video. "And I think we'll move forward with them."
The company hired Dr. Patterson as an adviser, in addition to hiring his company, IncellDx, to provide diagnostic services. CytoDyn and Dr. Patterson said his tenure as a consultant ended in May. CytoDyn also no longer uses Dr. Patterson's company for diagnostic services.
An April securities filing disclosed that Dr. Patterson was a CytoDyn shareholder.
In the interview with the Journal, Dr. Patterson said he never received paperwork regarding his ownership in CytoDyn . "I've gotten little to no paperwork regarding that," he said. "I don't think of it as real."
On the question of Dr. Patterson's share ownership, Arian Colachis , CytoDyn's general counsel, pointed to the April filing.
"The document speaks for itself, and we have no further comment," she said.
Write to Michael Wursthorn at Michael.Wursthorn@wsj.com
(END) Dow Jones Newswires
08-26-20 1145ET
Copyright (c) 2020 Dow Jones & Company, Inc.
We would probably both say Bruce is more often than not , the smartest guy in the room. I know having a $400,000 outstanding invoice from CYDY and a being out lots money on all those ccr5 test kits that ended up not be needed is probably is the biggest mistake he has made. But, his belief in the effectiveness of LL was never in question.
Yeah he did. But hey we all make mistakes!
I remember a fun zoom call with your buddy Bruce from July 2021. He had several cancer trial ideas and with several different pharma's, it was a tremendous call, he was so confident that he could change cancer treatments because of this drug.
Honestly, after the clown show Nader was, I do regret not voting yes for Paul & Bruce. Bruce loved this drug.
funny thing is your buddy Bruce did an hour long Ted Talk about how much he believed in this drug. And I do believe he was a leading canidate for potentially leading this company as president if the 13d was successful, infact, I was part of several zoom calls with Bruce telling us how he could fix the bla and have 100 million in funding if the 13d vote went his way.
So why so negitive???
in what context are you assuming this time? according to you...no thanks, I will pass.
$$CYDY$$ 2024
https://en.wikipedia.org/wiki/Leronlimab
https://en.wikipedia.org/wiki/CCR5 Yep, leronlimab. We got it. The big boys want it. There will be a deal. Bank on it.
Meanwhile, Go Sidley, Go Dr. J.
Looking good longs!!!! Save the planet yet?
CYDY back in da 14s today. BWWWAAAAAAHAHAHAHA!!!
Dupes touting leronsaline is safe as a tic tac. Who is dumb enough to believe a tic tac would cure HIV or covid then whine about the share price downfall is all the "bashers" fault?
LAUGHING
"Structured Settlement" talks means CYDY will be paying Amarex, not the other way around like the lololongs think. CYDY management is very scared about the likely bankruptcy.
Bruce is good, gained some weight tho. Trial is already up and running.
Hey buddy, how's Bruce these days. Don't you have a trial to fill up. Thanks for laying the ground work for a long covid for the ccr5 path. That way a better ccr5 drug can stop the liver damage you boys are up too.
After this old PR by CYDY, did the FDA SUBSEQUENTLY release ALL holds ensuring LL is safe?
“Truth or ‘bashing’?”
It’s clearly bashing when considering the facts.
IMOP
you could be right, and I do worry about that for sure. Jay seems like a smart guy and a straight shooter - but he's never pulled off anything like this before - this is a different beast than running Quest Diagnostics. and if he's still on the FDA's @#$% list, that's a double whammy against us.
Did CYDY in their own words tell the SEC they would remove language that states or implies that it believes leronsaline is safe and effective or that leronsaline is likely to be found safe and effective or not?
Yes or no? https://www.sec.gov/Archives/edgar/data/1175680/000119312521171425/filename1.htm
Truth or "bashing"?
Terrible bashing technique aimed at the Cytodyn. Can you find anything older? You really need to find a new employer
The problem is that per the emails released, I don’t think the FDA thinks any more of Jay than they did CYDY before Jay. That’s problematic given that Jay was to be the respected new face. Not sure where that all lands.
Is ((((((((LERONSALINE)))))))) safe and effective? NOPE!---
1. We note statements in your proposed disclosure for Item 1 and Note 4 that you believe leronlimab is safe and effective, as well as language implying the existence of “clinical data that supports its safety and efficacy.” As safety and efficacy determinations are within the authority of the U.S. Food and Drug Administration and comparable regulatory bodies, please revise your proposed disclosure to remove language that states or implies that you believe leronlimab is safe and effective or that leronlimab is likely to be found safe and effective.
RESPONSE:
The Company will revise its proposed disclosure to remove language that states or implies that it believes leronlimab is safe and effective or that leronlimab is likely to be found safe and effective.
https://www.sec.gov/Archives/edgar/data/1175680/000119312521171425/filename1.htm
Magic Mike gave a bs excuse of selling da shares to save da wife! I suspect he has cut a deal to testify against Nadir and Kazem.
How much does nada hate mully for not only selling at twice the price but also not getting into trouble. Dude must be fuming. THAT'S MY OPINION
Fair enough but is there a such thing as a CondeeeeeeEeEeEeEeEEtional EUA?
I would never invest in a biotech company that the FDA is laughing at. Seems like a no brainer.
Hey DJ - there is no such drug as leronliboob or whatever you referred leronlimab as. Recently someone named “justdafactss” referred to leronlimab as “leronsaline” many many times and it seems like he/she stopped doing this once I pointed out this inaccuracy.
True. We're talking a BLA scheme and a COVID scheme.
Kazem denies the COVID scheme.
LOL dont ask the obvious question
Its way easier for these bagholders to accuse the FDA than to question the obvious LOLOL
This keeps their convoluted story an appearance of truth when they have to explain to their family & friends why they have lost -97%
If leronlimoob is so great why aren't they running any clinical trials? Seems like a no brainer to me.
“Kazem vigorously asserts that he and Nodder ARE NOT TWO PEAS IN A POD.
The filing provides plenty of evidence to back up that assertion.”
EXCEPT that one time when NP said file the BLA no matter what’s missing, Amarex filed the BLA incomplete and both companies subsequently PRed that a completed BLA had been filed. Besides that part of the alleged fraud, no, not in the same pod.
i think you're right. I have always believed there is value in the drug itself. In the right hands, it could create a lot of value for investors. I placed way too much focus on the drug, and not nearly enough on the leadership side when making my investment decisions. But, what I have learned (the hard way) is that for any company to succeed, you must have both - a great product, and great execution by a solid leader.
What i cannot figure out now is whether the company (and my investment by extension) can survive NPs disastrous moves. I'm not discounting the FDA and their hatred of CYDY - but I am convinced that if we had a very credible leader in place, the regulators would have treated us completely differently. They have seen us as a problem child for many years - mostly because of the way NP has behaved.
I remain very concerned, but i don't think anyone knows for sure how this will play out - despite some saying they do.
Case: 8:2022cr00440 USA v. Pourhassan - Kazem Kazempour
Kazem vigorously asserts that he and Nodder ARE NOT TWO PEAS IN A POD.
The filing provides plenty of evidence to back up that assertion.
To reiterate
I've been reading posts on other boards and I have to say that there were so many smart people who had invested in CYDY three or + years ago. They definitely were ahead of the curve or more skeptical of NP and his wiley ways. Some of us, like me, only focused on the efficacy of Leronlimab - believing its Lazarus qualities while others had the right focus looking at NP and saying "What is he doing?" My inner voice still says Leronlimab is the real thing but how is it going to play out, now?
Today's court documents have harpooned both Nader and FDA members in separate ways to CYDY's downfall. The longs take it on the chin because these FDA blowhards, who incidentally are the ones in-charge and making new rules (not observing the rules) have played whack-a-mole with CYDY and thus, maybe killing the efficacy of Leronlimab, forever.
Yes, I expect some interviews with Nader et al....ET AL. Going to be quite the interesting story should one ever get published.
Some who don't expect it may get an interview as well. Be ready!! FDA and bashers will follow the Nader interview most likely.
May well trigger some other investigations to dig some more and make a few adjustments. Probably going to be a lot of squirming trying to get the stories straight.
Meanwhile, Sidley takes good notes and may well have some contributions to add to the story.
So in the interim, keep up the incrimination bashers ,and oh yes, thanks for the cheapies anytime.
In the interim, Dr. Jay is slaving away. Get ready.
$CYDY$ 2024
“Now show us the hold was lifted in the 10Q”
Not sure what you’re referring to. The clinical hold was lifted months ago and I’m confident it was filed in an 8k and mentioned in the 10q, just like NP’s felony convictions.
Now show us the hold was lifted in the 10Q lol
“And his second conviction was , his check for $100.00 bounced ,
well , when I was an intern in the hospital , many of my checks bounced ....I must be the biggest criminal in USA , everyone else are angles here ..”
If you believe anyone is charged with felony fraud for accidentally bouncing a check for $100, then I have a bridge to sell you. That pattern was there for all to see, some caught it, some didn’t, but no coincidence he’s pending a 3rd felony.
No , today you cant be arrested for assaulting police officer , or anyone on the street .
Or if you have a bad luck and someone will arrest you , you are back on the street in few hrs.
But I guess their crime was not as big as Dr NP , sending an email to his x-wife asking about their son.
Go figure.
All imo.
And in today’s society, you can be arrested for assaulting a police officer and then get back out on the streets to do it again.
My how times have changed.
" Dr NP was convicted of sending an email to his x-wife. " email was about their child.
WOW , he is really a CONVICT , I hope the whoever is attacking him didn't make a bigger sin in their past , I am sure I may do something worse then that !!..
And his second conviction was , his check for $100.00 bounced ,
well , when I was an intern in the hospital , many of my checks bounced ....I must be the biggest criminal in USA , everyone else are angles here ..
And then he filed for BK , well , millions of Americans doing this , is this consider to be a criminal act in USA ???
Only the 5.95s must be the saints I see. Average person in USA will be happy to have ONLY those crimes against them ..
All imo.
GLTA longs
“The following information may be relevant to an investor’s evaluation of Dr. Pourhassan, as well as an investor’s decision to buy, sell or hold securities of the Company:
a. On May 3, 2006, in Superior Court of Washington for Clark County Case No. 204227D, Dr. Pourhassan was convicted of a felony domestic violence court order violation. Dr. Pourhassan pled guilty to violation of the provisions of a protection order by contacting his former spouse via email with communication intended for his son. Dr. Pourhassan performed community service, paid a fine of $100, served 24 months of probation and was ordered to comply with the protection order.
b. On June 9, 1986, in the First District Court in Logan, Utah, Dr. Pourhassan was convicted of a third-degree felony of theft by deception for overdrawing his bank account by approximately $100. Dr. Pourhassan was placed on one-year probation.
c. Dr. Pourhassan filed for Chapter 7 Bankruptcy in 1991 in Salt Lake City, Utah, case number 91-24348, and in 2001 in Portland, Oregon in case number 01-36712-elp7.”
FELONY domestic violence and FELONY of theft by deception (deception like maybe the BLA isn’t complete?). Great CEO material!
https://www.cytodyn.com/investors/sec-filings/all-sec-filings/content/0001193125-12-392638/d412647d8k.htm?TB_iframe=true&height=auto&width=auto&preload=false
In some cases Leronlimab (or Leronmybud LL) will "carry the ball across the goal," (Especially where CCR5 is involved) but more frequently, it would be a valuable adjuvant. And the, so far, minimal negative side-effects... give it some interesting advantages.
And
Makes >> LL >>> A THREAT <<< to competing drugs carrying "heavy side-effect disadvantages."
So spin us a tale on ...HOW >>>Roger Stone get some LL for his wife with (reputedly) good results?
And it seems some other "biggies" got some.
But now >>> LL could gradually, become the Newest Drug. A drug that seems to support health by helping to counter chronic inflammation. But LL's not a magic bullet.
A lot of factors apply - like what are you're eating, breathing, sharing, and on and on, etc.
But Leronlimab, Leronmybud, is something I want available.
My Opinion totally!!
***
And, sorry big-bully Pharma. We could have been working together, but events have a path of their own,
Imagine
Leronlimab
Could be
Popping up
Leronmybud
And they have their own
"on-line Docs"
to do the scripts ;)
Always entirely my opinion - do your own research
Me skeptical?
And what IS happening with the "waste Leroonlimab?"
The "game is afoot," (an allusion to 'Sherlock Holmes').
Sure, they're going to just "flush >>> the ultimate new cure >> down the drain or the collective toilets in S. Korea?
Realllllly?
(And even if it's not a proven fact...makes a delicious rumor...suggesting the drug might suddenly "appear from afar.")
And the product and formula are totally gone or beyond analysis and replication? Right!!!!!
And Suddenly...
"Hello there"
It's your 'new friend'
Leronmybud!
Yeah, it's down there, to the left of bagged fortune cookies under, yeah, the counter full of "lucky bamboo." So, cash, card, or Dillo?
And big pharma is caught "stupidly standing" as the wonder drug becomes readily available from other sources.
***
I suspect >>>it's available right now...
But not for us.
***
All my opinion
Would you take a truckload of "hope Diamonds" and dump them in the deepest ocean...(without a net cleverly concealed)?
Hmmmm?
The pen-ultimate "Ha, ha?"
Our big pharma, after battering poor old CytoDyne (My opinion)" will be lost in the dust...
Yes this mother is in medical profession-- More fucking lies from you.
A mother IN the medical profession is either currently licensed or employed via proof of paying taxes on income of said medical profession. You are neither.
A retired doctor is just that. Lets see a retired unlicensed doctor perform a surgery in a clinic or hospital. That being said, he or she is no longer a doctor.
A washed up liar losing money on a OTC penny stock is a more fitting definition of a pumping individual whom is NOT in the medical profession.
lol , you really trying with your lies and attack on people .
Yes this mother is in medical profession ,
Retired doctor is still a doctor … .
But you knew this .
Find yourself something more productive to do for living , This insulting people for money is sickening .
All imo
Truth??? These are both LIES--- 1. "a mother in the medical field" (which is patently false, the mother WAS NOT licensed in the medical field at the time of this article).
2. "CytoDyn, appears to be the only biotech company with a proven treatment in a large randomized controlled trial for severe and critical COVID-19." which is ANOTHER blatant lie.
Which online financial publication had the story of leronlimab damaged their twins posted?
Was it posted on Zerohedge?
Zerohedge says--- the zero hedge manifesto
our mission:
to widen the scope of financial, economic and political information available to the professional investing public.
https://www.zerohedge.com/about
Dont even get me started on the never purchased CYDY warrants at a discounted price lies.
Followers
|
814
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
233448
|
Created
|
11/18/05
|
Type
|
Free
|
Moderators janice shell kgromax |
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |